Conclusions—These results indicate that P-selectin interaction with a ligand, different from PSGL-1 or GP Ib, stabilizes initial GP IIb/IIIa–fibrinogen interactions, allowing the formation of large ...

How many platelet GP IIb/IIIa receptor sites need to be occupied to provide protection ... role for inhibitors of platelet adhesion that antagonize platelet glycoprotein Ib receptors with a relatively ...

Use of GP IIb/IIIa inhibition in these patients, particularly in combination with thrombolytic therapy or during "rescue" PCI, should be undertaken with caution.

The C-statistic for the risk-adjusted mortality index was >0.916 for all three GP IIb/IIIa-receptor models. Similarly, for the risk-adjusted complications index, the C-statistic was >0.789 for all ...

While glycoprotein (GP) IIb/IIIa inhibitors have been widely studied in ischemic stroke, cangrelor remains less explored. Objective To evaluate the safety and efficacy of cangrelor compared with GPIIb ...

Background Cangrelor, an intravenous P2Y12-receptor inhibitor, is a reversible and short-acting antithrombotic medication non-inferior to irreversible glycoprotein IIb/IIIa inhibitors (GPIs) like ...

From a cardiological perspective, this has not proved to be the case. The guidelines issued on implantable defibrillators, intracoronary stents, and glycoprotein (GP) IIb/IIIa inhibitors have been ...

Switzerland Objective To assess the cost-effectiveness of bivalirudin versus heparin and glycoprotein IIb/IIIa inhibitor (H-GPI) in patients undergoing primary percutaneous coronary intervention (PPCI ...

Binding of soluble fibrinogen to the activated conformation of the integrin αIIbβ3 is required for platelet aggregation and is mediated exclusively by the C-terminal AGDV-containing dodecapeptide ...

HAV genotypes I, III and V were identified as circulating in LMICs. HAV genotypes I and V were reported in Southern Africa, while HAV subgenotypes IIIA, IB and IA were reported in Asia, and HAV ...